Compare DEI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | STOK |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2006 | 2019 |
| Metric | DEI | STOK |
|---|---|---|
| Price | $11.93 | $32.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $12.94 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 2.4M | 609.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.06% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,982,000.00 | $184,420,000.00 |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | $2.35 | $77.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.77 | ★ 404.50 |
| 52 Week Low | $9.04 | $11.19 |
| 52 Week High | $16.94 | $40.22 |
| Indicator | DEI | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 55.20 |
| Support Level | $11.13 | $30.34 |
| Resistance Level | $12.58 | $35.11 |
| Average True Range (ATR) | 0.37 | 1.54 |
| MACD | -0.09 | 0.28 |
| Stochastic Oscillator | 38.10 | 73.88 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.